CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025
CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has scheduled its Q4 and Full Year 2024 financial results announcement. The company will release its financial performance report before market opens on March 25, 2025, followed by a corporate update conference call at 8:30am Eastern Time.
CorMedix (Nasdaq: CRMD), un'azienda biofarmaceutica specializzata in prodotti terapeutici per malattie potenzialmente letali, ha programmato l'annuncio dei risultati finanziari del Q4 e dell'anno intero 2024. L'azienda pubblicherà il suo rapporto sulle performance finanziarie prima dell'apertura del mercato il 25 marzo 2025, seguito da una conferenza telefonica di aggiornamento aziendale alle 8:30 ora orientale.
CorMedix (Nasdaq: CRMD), una empresa biofarmacéutica especializada en productos terapéuticos para enfermedades que amenazan la vida, ha programado el anuncio de sus resultados financieros del Q4 y del año completo 2024. La compañía publicará su informe de rendimiento financiero antes de la apertura del mercado el 25 de marzo de 2025, seguido de una conferencia telefónica de actualización corporativa a las 8:30 a.m. hora del Este.
CorMedix (Nasdaq: CRMD), 생명을 위협하는 질병에 대한 치료 제품을 전문으로 하는 생명공학 회사가 2024년 4분기 및 연간 재무 결과 발표 일정을 잡았습니다. 이 회사는 2025년 3월 25일 시장 개장 전에 재무 성과 보고서를 발표하고, 동부 표준시 오전 8시 30분에 기업 업데이트 컨퍼런스 콜을 진행할 예정입니다.
CorMedix (Nasdaq: CRMD), une entreprise biopharmaceutique spécialisée dans les produits thérapeutiques pour les maladies menaçant la vie, a programmé l'annonce de ses résultats financiers pour le Q4 et l'année complète 2024. L'entreprise publiera son rapport de performance financière avant l'ouverture du marché le 25 mars 2025, suivi d'une conférence téléphonique de mise à jour de l'entreprise à 8h30 heure de l'Est.
CorMedix (Nasdaq: CRMD), ein biopharmazeutisches Unternehmen, das sich auf therapeutische Produkte für lebensbedrohliche Krankheiten spezialisiert hat, hat die Bekanntgabe seiner Q4- und Jahresergebnisse 2024 angesetzt. Das Unternehmen wird seinen Finanzbericht vor Markteröffnung am 25. März 2025 veröffentlichen, gefolgt von einer Unternehmensupdate-Konferenzschaltung um 8:30 Uhr Eastern Time.
- None.
- None.
BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time.
| Tuesday, March 25th @ 8:30am ET | ||
| Domestic: | 1-844-481-2557 | |
| International: | 1-412-317-0561 | |
| Conference ID: | 10197392 | |
| Webcast: | Webcast Link | |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When will CorMedix (CRMD) release its Q4 2024 earnings?
What time is CorMedix (CRMD) Q4 2024 earnings call?
What period will CorMedix (CRMD) financial results cover?
What is CorMedix (CRMD) business focus?
